Vittal Mallya Scientific Research Foundation v. Indus Biotech Private Limited

In the high-stakes world of intellectual property, filing a lawsuit is often the loudest signal a company can send. But what happens when the plaintiff, after all the buildup, simply decides not to press forward? The case of Vittal Mallya Scientific Research versus Indus Biotech Private Limited offers a fascinating look at how a patent infringement battle can end not with a bang, but with a quiet withdrawal — and what that means for founders who treat litigation as a strategic tool rather than a guaranteed win.

Vittal Mallya Scientific Research, a research institution holding several process patents, found itself at odds with Indus Biotech Private Limited, a company it accused of manufacturing and selling products that allegedly infringed those patents. The products in question were a soluble double metal salt of HCA (hydroxycitric acid) and anti-obesity beverages — a niche but commercially significant space in the health and wellness market. Believing its patented processes were being violated, Vittal Mallya Scientific Research filed a civil suit seeking permanent injunctions to stop Indus Biotech from continuing its allegedly infringing activities. The suit set the stage for what could have been a substantial patent infringement showdown.

On one side stood Vittal Mallya Scientific Research, armed with its process patents and a claim that Indus Biotech's manufacturing and sale of HCA-based products and anti-obesity beverages constituted infringement. The relief sought was significant: a permanent injunction that would halt the defendant's production entirely. On the other side was Indus Biotech Private Limited, which presumably contested the allegations of patent infringement. The legal friction centered on whether Indus Biotech's processes fell within the scope of the plaintiff's patented methods. However, the battle never reached a full judicial resolution — because the plaintiff itself altered the course of the proceedings.

Rather than pressing its claims to a final judgment, Vittal Mallya Scientific Research moved to withdraw the suit, marking it as 'not pressed.' The court accepted this withdrawal and dismissed the case. The dismissal underscored a fundamental procedural reality: when a plaintiff chooses not to pursue its own claims, the court has little choice but to close the matter. Even though the question of whether Indus Biotech had infringed valid process patents remained unanswered, the legal chapter ended with the case being dismissed — leaving the underlying dispute unresolved on its merits.

For founders and IP professionals, this case carries a clear and practical lesson: filing a patent infringement suit is not the same as winning one. If you initiate litigation and then choose to withdraw it as 'not pressed,' the court will dismiss the case — and your patents remain untested in that forum. Before filing, ensure you have the evidence, resources, and strategic commitment to see the fight through. A withdrawn suit not only wastes time and legal spend but also leaves the alleged infringer free to continue its activities and gives them a preview of your legal arguments. Treat litigation as a deliberate, well-prepared offensive — not a move you can easily take back.